GU Cancers 2026 | VIR-5500 PSMA–CD3 T-cell engager shows promise in prostate cancer
Ben Tran, MBBS, FACP, Peter MacCallum Cancer Centre, Melbourne, Australia, provides an overview of VIR-5500, a T-cell engager targeting PSMA and CD3, for prostate cancer, highlighting its innovative masked design that activates immune cells only within the tumor microenvironment. This approach has yielded impressive PSA response rates and potentially durable outcomes, making it a promising treatment option for prostate cancer. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I’m really excited by VIR-5500. So this is a T-cell engager. I’ve spent a lot of my career developing T-cell engagers in prostate cancer. This is a T-cell engager against PSMA, but also engaging T-cells through CD3. And the interesting thing about it is it’s masked on both sides, which means it doesn’t activate the immune cell until it gets into the tumor microenvironment...
So I’m really excited by VIR-5500. So this is a T-cell engager. I’ve spent a lot of my career developing T-cell engagers in prostate cancer. This is a T-cell engager against PSMA, but also engaging T-cells through CD3. And the interesting thing about it is it’s masked on both sides, which means it doesn’t activate the immune cell until it gets into the tumor microenvironment. And the result is just outstanding. So very high PSA response rates and hopefully great durability as well. But I think that’s a really promising treatment for prostate cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
